Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; difficulties or delays in manufacturing, marketing and obtaining regulatory approval for ANX-530, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-530 and other challenges by patent holders during the Section 505(b)(2) process; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its goals, including funding the continued development and commercialization of ANX-530; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; patent and non-patent exclusivity covering Navelbine; ADVENTRX's lack of long-term agreements with suppliers of ANX-530 components and contract manufacturers of ANX-530, including its inability to timely secure commercial quantities of ANX-530 or its components on commercially reasonable terms, or at all; uncertainty under Section 505(b)(2) resulting from legal action against the FDA and the potential that future interpretations of Section 505(b)(2) could delay or prevent the FDA from approving any Section 505(b)(2) NDA; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has ... (London, UK - November 19-20, 2015)" conference to ... will cover industry case studies, regulatory updates, latest therapies ... Dr Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar ...
(Date:9/2/2015)... 2, 2015   Gulf Coast Tattoo Removal is the ... cutting-edge Astanza Duality laser in Southern Mississippi . ... tattoo regret and take back control of their skin. The clinic ... its services to Biloxi , Gulfport ... tattoo regret being as prevalent as it is, I was surprised ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ... "Medical Device Studies: Clinical Evidence (London, UK - ... This course has been designed ... clinical evidence required for medical devices and in-vitro ... medical devices and the emphasis on high quality, ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... EyeScience(TM) ( www.eyescience.com ) announced today that their ... and Dry Eye Formula(TM) are the only ocular ... their offices and through mass market retail. This announcement comes ... demand for the most complete eye vitamins available for AMD ...
... , KYOTO, Japan and PRINCETON, N.J., Nov. 11 ... NJ, USA) today announced that both parties have entered ... based on the Radiography System of Shimadzu featuring its ... applications. , This partnership contains ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3Shimadzu and EDDA Announce Business Partnership on X-ray Chest CAD Applications 2Shimadzu and EDDA Announce Business Partnership on X-ray Chest CAD Applications 3
(Date:9/2/2015)... ... September 02, 2015 , ... According to an article published August 12 by International ... aims to do away with grand juries in cases meant to decide if a police ... response to grand jury decisions in Ferguson and New York City that absolved police officers ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... – in the news recently following a decision by the Centers for Medicare ... is likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announced today the launch of its enhanced, cloud-based mobile ePrescribing application. The release ... focus on improving prescriber usability. A leader in health technology, RxNT was one ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... incoming goods, intermediate or final products. Automating sample handling makes density measurements more ... handling, showing each step of the automated workflow and the advantages compared to ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... on the development and commercialization of proprietary pharmaceuticals ... partners , today announced that under the Special ... with the United States Food and Drug Administration ... protocol for crofelemer for the treatment of chronic ...
... Functional foods could be the rage today in advanced ... better ask some tough questions before they decide ... ,Currently the international functional foods market is a ... ,* Margarines that lower bad cholesterol (LDL). ...
... at the University of Southern California have applied a ... clear up an old puzzle of the global carbon ... an advanced online publication of The ISME Journal. ... for nanometer-scale, secondary ion mass spectrometry) located at Lawrence ...
... to get hookah smoking exempted from Englands smoking ban ... the health effects , doctors writing in this weeks ... ,A hookah is a glass based waterpipe used ... for smoking herbal fruits after meals, but it is ...
... disease gives a more accurate measure of how many UK ... adults are most likely to benefit from treatment . ... the general population without pre-existing cardiovascular disease or diabetes, there ... Britain at high risk of developing heart disease. This is ...
... and Children's Hospital, Adelaide in Australia has raised serious questions ... are exposed to every day. ,Titled The ... ageing facilities in two of the hospital's oldest buildings and ... ,It states: "WCH is experiencing immediate facilities, infrastructure and related ...
Cached Medicine News:Health News:Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer 2Health News:Functional Food What is That, Ask First 2Health News:Functional Food What is That, Ask First 3Health News:Nanospectrometer Aids in Identifying Nutrient Cycle 2Health News:Ban on Hookah Smoking Should Stay, Argue Doctors 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 2Health News:New Heart Disease Risk Score Will Help Minimise Health Inequalities 3Health News:Concerns Raised Over Risks for Patients and Staff in Australian Hospital 2
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: